Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan Xiong, MS, Jay Lin, PhD, Prajesh Kothawala, MD, MPH, Matthew Emons, MD, MBA The American Journal of Medicine Volume 123, Issue 5, Pages 446-453 (May 2010) DOI: 10.1016/j.amjmed.2009.11.015 Copyright © 2010 Elsevier Inc. Terms and Conditions
Figure 1 Patients meeting study inclusion/exclusion criteria. The American Journal of Medicine 2010 123, 446-453DOI: (10.1016/j.amjmed.2009.11.015) Copyright © 2010 Elsevier Inc. Terms and Conditions
Figure 2 Patients stratified by CHADS2 (Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke) score. The American Journal of Medicine 2010 123, 446-453DOI: (10.1016/j.amjmed.2009.11.015) Copyright © 2010 Elsevier Inc. Terms and Conditions
Figure 3 Warfarin use within 30 days of first recorded atrial fibrillation/flutter diagnosis, by stroke risk level. *Hatched area represents the proportion of patients with uninterrupted therapy over 180 days following their initial warfarin prescription. CHADS2=Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke score. The American Journal of Medicine 2010 123, 446-453DOI: (10.1016/j.amjmed.2009.11.015) Copyright © 2010 Elsevier Inc. Terms and Conditions